share_log

天演药业宣布将出席2024年 Leerink Partners 全球生物医药大会

TianYan Pharmaceutical announced that it will attend the 2024 Leerink Partners Global Biomedical Conference

PR Newswire ·  Feb 27 18:00

Suzhou, China and San Diego, USA, Feb. 28, 2024/PRNewswire/ -- Tianyan Pharmaceutical (“Company” or “Tianzhan”) (NASDAQ: ADAG) is a platform-driven clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapeutics based on original antibodies. The company announced today that it will attend the Leerink Partners Global Biopharma Conference 2024 (the Leerink Partners Global Biopharma Conference 2024) to be held from March 11th to 13th in Miami, Florida, USA. During the conference, Dr. Luo Peizhi, Chairman of the Board of Directors, CEO and President of R&D of Tianyan Pharmaceutical, will deliver a speech on anti-CTLA-4 SafeBody ADG126 to share its latest developments, including key milestones in 2024. At that time, the company's management team will also host relevant investor meetings.

Details of the conference are as follows:

Meeting Date: Tuesday, March 12, EST

Presentation time: 13:40 EST

Conference venue: The Fontainebleau Miami (The Fontainebleau Miami), Miami Beach

At that time, you can visit the TianYan Investor Relations website and watch the webcast: link (30-day playback is supported).

About Tianyan Pharmaceutical

Tianyan Pharmaceutical (NASDAQ: ADAG) is a platform-driven biopharmaceutical company with a clinical product development stage produced by an independent platform. The company is committed to discovering and developing novel cancer immunotherapy based on original antibodies. Using computational biology and artificial intelligence, with its world-first three-body platform technology (new epitope antibody NeoBody, safe antibody SafeBody and Strong Antibody (PowerBody), Tianyan Pharmaceutical has established a unique and original antibody product line focusing on novel tumor immunotherapy to address unmet clinical needs. Tianyan has reached strategic partnerships with a number of world-renowned partners, and uses its various original cutting-edge technologies to empower partners to develop new drugs.

For more information, please visit:  Also pay attention to Tianyan PharmaceuticalWeChat,LinkedInandTwitterOfficial account.

SafeBody It is a registered trademark of Tianyan in the US, China, Australia, Japan, Singapore and the European Union.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment